Across TCGA pan-cancer cohorts, BLCAP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BLCAP data layer compared with 26 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher BLCAP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BLCAP expression acts as an unfavorable survival marker.
CESC and UCEC are the cancer types where BLCAP Mutation most reproducibly stratifies survival.